KOSIN UNIVERSITY COLLEGE OF MEDICINE
Search
- Page Path
- HOME > Search
- Central diabetes insipidus following COVID-19 mRNA vaccination: a case report
- Min-Young Kim, Jong Ryeal Hahm, Jaehoon Jung, Jung Hwa Jung, Kyoung Young Kim, Hosu Kim, Jong Ha Baek, Hwa Seon Shin, Kee Ryeon Kang, Soo Kyoung Kim
- Kosin Med J. 2023;38(3):219-223. Published online June 9, 2023
- DOI: https://doi.org/10.7180/kmj.23.105
- 1,165 View
- 28 Download
-
Abstract
PDF
PubReader 
ePub
- The coronavirus disease 2019 (COVID-19) has been a major public health emergency worldwide. Vaccines were rapidly developed and approved to prevent the spread of viral infection. However, various side effects of the COVID-19 messenger RNA (mRNA) vaccines have been reported after their commercialization. A 24-year-old man visited our emergency department with polyuria and polydipsia that occurred after he received a COVID-19 mRNA vaccine 10 days beforehand. The initial laboratory findings showed very low urine osmolality with hyperosmolar hypernatremia. Based on these findings, diabetes insipidus was suspected, and sella magnetic resonance imaging showed an enlarged pituitary gland and the absence of posterior pituitary higher intensity. After 12 hours of using oral desmopressin acetate, urine volume decreased, and after 5 days of administration, serum electrolyte and serum osmolality improved. This case report of diabetes insipidus occurring after vaccination with the BNT162b2 mRNA COVID-19 vaccine is presented as a reminder that close monitoring is necessary for patients with polyuria and polydipsia after vaccination.
- Obese Subjects with Non-Alcoholic Fatty Liver Disease Have a Higher Risk of Thyroid Dysfunction
- Minyoung Kim, Soo Kyoung Kim, Jaehoon Jung
- Kosin Med J. 2019;34(2):117-125. Published online December 31, 2019
- DOI: https://doi.org/10.7180/kmj.2019.34.2.117
- 1,510 View
- 5 Download
- 1 Citations
-
Abstract
PDFPubReader ePub
Objectives The effects of obesity on thyroid function have not been well established. The aim of this study was to investigate the effects of body mass index (BMI) and/or non-alcoholic fatty liver disease (NAFLD) on thyroid function.
Methods A retrospective longitudinal analysis was conducted among subjects who underwent comprehensive health check-ups at least four times between 2008 and 2017. Thyroid function was investigated according to BMI or presence of NAFLD at the end of follow-up. The subjects were divided into four groups: control (n = 216), subjects with obese (n = 94), subjects with NAFLD (n = 48), and subjects with obese + NAFLD (n = 93). Obesity was defined as BMI ≥ 25 kg/m2.
Results During the mean follow-up of 6.8 years (6.8 ± 1.2 years), 42 of the 451 subjects (9.3%) had subclinical hypothyroidism (SCH) but no subjects developed overt hypothyroidism. In multivariate Cox proportional hazard analysis, after adjustment for age, sex, smoking, and baseline thyroid stimulating hormone level, obese subjects with NAFLD had a higher risk of SCH than the control group.
Conclusions The obese subjects with NAFLD had a higher risk for SCH in the future.
-
Citations
Citations to this article as recorded by
- Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
Daniela Maria Tanase, Evelina Maria Gosav, Ecaterina Neculae, Claudia Florida Costea, Manuela Ciocoiu, Loredana Liliana Hurjui, Claudia Cristina Tarniceriu, Mariana Floria
International Journal of Molecular Sciences.2020; 21(16): 5927. CrossRef
- Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
A Case of Cerebral Venous Thrombosis in a Patient with Graves' Disease - Bo Ra Kim, Jung Hwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Hee Jung Park, Soo Kyoung Kim
- Kosin Med J. 2016;31(2):179-183. Published online January 20, 2016
- DOI: https://doi.org/10.7180/kmj.2016.31.2.179
- 1,201 View
- 3 Download
- 1 Citations
-
Abstract
PDFPubReader ePub
Abstract Superior sagittal sinus thrombosis is an uncommon disease, and 25% of cases are considered to be idiopathic. Hypercoagulability, local bloodstream stasis, and vessel wall abnormalities may contribute to the development of this condition. The thyrotoxic phase of Graves' disease is associated with venous thrombosis caused by hypercoagulability, which is in turn induced by increased levels of homocysteine and factor VIII and decreased fibrinolytic activity. Here, we report the case of a 39-year-old male who presented with superior sagittal sinus thrombosis and concomitant hyperthyroidism.
-
Citations
Citations to this article as recorded by- Cerebral Venous Thrombosis during Thyrotoxicosis: Case Report and Literature Update
Emanuela Maria Raho, Annibale Antonioni, Niccolò Cotta Ramusino, Dina Jubea, Daniela Gragnaniello, Paola Franceschetti, Francesco Penitenti, Andrea Daniele, Maria Chiara Zatelli, Maurizio Naccarato, Ilaria Traluci, Maura Pugliatti, Marina Padroni
Journal of Personalized Medicine.2023; 13(11): 1557. CrossRef
- Cerebral Venous Thrombosis during Thyrotoxicosis: Case Report and Literature Update
Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up - Jong-Ha Baek, Bo Ra Kim, Jeong Woo Hong, Soo Kyoung Kim, Jung Hwa Jung, Jaehoon Jung, Jong Ryeal Hahm
- Kosin Med J. 2016;31(2):146-156. Published online January 20, 2016
- DOI: https://doi.org/10.7180/kmj.2016.31.2.146
- 945 View
- 4 Download
-
Abstract
PDFPubReader ePub
Abstract Objectives To evaluate the efficacy and predictive factors of Dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes mellitus (T2DM) patients who were not well controlled with other oral antidiabetic drugs or insulin in real clinical practice.
Methods From December 2012 to January 2014, retrospective longitudinal observation study was conducted for patients with T2DM who were not reached a glycemic target (glycated hemoglobin [HbA1c] > 6.5%) with other oral antidiabetic drugs or insulins. Type 1 diabetes or other types of diabetes were excluded. Responders were eligible with decreased HbA1c from baseline for more than 5% during follow up period.
Results Of total 135 T2DM patients having an average 9.0 months follow-up period, 84 (62.2%) of patients were responder to DPP-4 inhibitors. After concomitant treatment with DPP-4 inhibitors, patients had a mean decrease in HbA1c of 0.69 ± 1.3%, fasting plasma glucose of 13 ± 52 ㎎/㎗, and postprandial plasma glucose of 29 ± 85 ㎎/㎗ from baseline (all P< 0.05). Independent predictive factor for an improvement of glycemic control with DPP-4 inhibitors was higher baseline HbA1c (odds ratio 2.07 with 95% confidence interval 1.15–3.72) compared with non-responders.
Conclusions A clinical meaningful improvement in glycemic control was seen when DPP-4 inhibitors were added to other anti-diabetic medications in patients with T2DM regardless of age, duration of T2DM, type of combination treatment regimen. Patients who had higher HbA1c were more easily respond to DPP-4 inhibitors treatment in short-term follow-up period.
First
Prev
